The counterfeit GLP-1 problem is no longer hypothetical. It's documented, it's growing, and it directly affects patients buying through telehealth platforms, social media sellers, and international pharmacies.
Understanding what's been seized and how counterfeits enter the supply chain helps you evaluate whether your current medication source is at risk — and gives you the verification tools to check for yourself.
What's been seized in 2026
Three categories of counterfeit GLP-1 products have been intercepted by federal agencies this year.
Fake brand-name pens
Customs and Border Protection has seized shipments of counterfeit Ozempic and Wegovy pens, primarily originating from China and Turkey. The packaging is sophisticated — holographic stickers, batch numbers, QR codes — but the pens contain either no active ingredient, sub-therapeutic doses, or unidentified compounds. The FDA has issued specific import alerts for semaglutide pen devices from non-authorized sources.
These fakes typically enter the U.S. through international mail, are sold on social media platforms (Facebook Marketplace, Telegram groups, TikTok shops), and are priced significantly below legitimate wholesale cost. If someone is selling you an "Ozempic pen" for $150 without a prescription, it's not real Ozempic.
Mislabeled compounded vials
State pharmacy board investigations in Florida and Arizona have uncovered compounding operations producing vials labeled as semaglutide or tirzepatide with potency levels significantly different from what the label states. In some cases, vials contained less than 60% of the labeled dose. In at least one case, a vial labeled as semaglutide contained no detectable GLP-1 agonist at all.
These aren't "counterfeits" in the traditional sense — they're legitimacy failures within the compounding supply chain. The pharmacy may hold a valid license. The label may look correct. But the product inside the vial doesn't match what the label claims.
Research-grade peptides sold as prescription medication
The gray-market peptide vendor ecosystem — websites selling "research-grade semaglutide" without a prescription — continues to grow. These products are not prescribed, not pharmacy-compounded, and not regulated. They're marketed with disclaimers like "not for human consumption" while clearly targeting human consumers. Purity, potency, and sterility are entirely unverified unless the buyer independently commissions third-party testing.
How to verify your medication
If your medication comes from a legitimate telehealth platform that uses a licensed compounding pharmacy, the risk of receiving a counterfeit product is low but not zero. Here's how to verify.
Check the vial label
A legitimate compounded medication label includes the pharmacy name and address, the drug name and concentration (e.g., "Semaglutide 5mg/mL"), a lot or batch number, a beyond-use date (not just an expiration date — compounded products use beyond-use dating per USP guidelines), storage instructions, and the prescribing clinician's name.
If any of these elements are missing, contact the platform and ask for clarification. Missing label elements are both a regulatory violation and a signal that the pharmacy's labeling processes may not meet standards.
Verify the pharmacy
Ask your platform for the compounding pharmacy's name and license number. Cross-reference it against the state pharmacy board's online verification tool and the NABP database. Check whether the pharmacy has any pending or resolved disciplinary actions.
Request a Certificate of Analysis
Reputable compounding pharmacies conduct potency and sterility testing on each batch. Some will provide a Certificate of Analysis (CoA) to patients upon request — usually through the telehealth platform. A CoA from a third-party laboratory confirming the drug identity, concentration, and sterility provides the strongest verification available to individual patients.
Physical inspection
While not definitive, visual inspection catches some obvious problems. The solution should be clear and colorless (semaglutide) or clear to slightly opalescent (tirzepatide). Any cloudiness, particulate matter, discoloration, or unusual odor is grounds for not using the product and reporting it immediately. The vial cap should show no signs of tampering — no scratches, no resealing marks, no misalignment.
Where the supply chain is safest
The counterfeit risk varies dramatically by source. In order from lowest to highest risk:
Lowest risk: Brand-name medications from retail pharmacies. Wegovy, Zepbound, and Mounjaro purchased through a licensed retail or mail-order pharmacy with a valid prescription carry the lowest counterfeit risk. The supply chain is controlled from manufacturer to distributor to pharmacy, with serialization tracking at each step.
Low risk: Compounded medications from named 503B facilities. FDA-registered 503B outsourcing facilities operate under cGMP requirements and FDA inspection. Products from these facilities have a regulated chain of custody.
Moderate risk: Compounded medications from 503A pharmacies with documented testing. State-regulated 503A pharmacies that conduct and document per-batch potency and sterility testing through third-party labs represent a reasonable middle ground. The key variable is whether the specific pharmacy maintains these standards — which is why naming the pharmacy is essential.
High risk: Any product purchased without a prescription. No legitimate pathway exists for obtaining semaglutide or tirzepatide without a prescription in the United States. Any vendor that sells without requiring a prescription is either breaking the law or selling an unregulated product — or both.
What to do if you suspect a problem
If you believe you've received a counterfeit, substandard, or mislabeled GLP-1 product, take these steps in order:
Stop using the product. Do not inject anything you suspect may be counterfeit or contaminated.
Preserve the evidence. Keep the vial, packaging, shipping label, and any documentation. Photograph everything, including lot numbers and the pharmacy label.
Report to the FDA via MedWatch. The FDA's MedWatch system accepts reports of product quality problems, adverse events, and suspected counterfeits. The lot number from your vial is the most useful piece of information you can provide.
Report to your state pharmacy board. If the product came from a compounding pharmacy, the state pharmacy board where the pharmacy is located is the primary regulatory body. Provide the pharmacy name, your lot number, and a description of the concern.
Contact your telehealth platform. Document the platform's response. A legitimate platform will take the report seriously, investigate with their pharmacy partner, and provide a replacement if warranted. A platform that dismisses the concern or goes silent is telling you everything about its priorities.